FDA Approves First-in-Class Androgen Inhibitor Acne Cream |
Clinical News
eMediNexus Coverage from: 
FDA Approves First-in-Class Androgen Inhibitor Acne Cream

0 Read Comments                

The USA FDA has granted approval to clascoterone cream 1%, a first-in-class topical treatment for acne, stated the drugmaker Cassiopea.

This androgen receptor inhibitor is indicated for the treatment of acne vulgaris in male and female patients aged 12 years and above. The drug has been shown to reduce sebum production and inflammation in preclinical and clinical studies. This is the first acne treatment with a new mechanism of action approved in approximately 40 years and is expected to be available in the U.S. around early next year. The approval is based on two clinical trials that noted significant improvement in inflammatory as well as noninflammatory lesions after 12 weeks with twice-daily topical application of the drug… (Medpage Today)

To comment on this article,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now